Jay O. Knipe
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect(2010)931 cited
- → Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity(2002)540 cited
- → Synthesis and Structure−Activity Relationships of 3-Aryloxindoles: A New Class of Calcium-Dependent, Large Conductance Potassium (Maxi-K) Channel Openers with Neuroprotective Properties(2002)186 cited
- → Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)(2012)183 cited
- → The synthesis and characterization of BMS-204352 (MaxiPost™) and related 3-fluorooxindoles as openers of maxi-K potassium channels(2002)182 cited
- → Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications(1997)167 cited
- → New hydrazone derivatives of Adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity(1991)162 cited
- → An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion(2008)133 cited
- → Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol®), mitomycin C and doxorubicin(1998)113 cited
- → The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection(2014)110 cited